Literature DB >> 15384976

Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas.

Bernard Drénou1, Marcel Tilanus, Gilbert Semana, Mehdi Alizadeh, Brigitte Birebent, Jean-Marc Grosset, Patricia Dias, Dick van Wichen, Yvonne Arts, Dianne De Santis, Renée Fauchet, Laurence Amiot.   

Abstract

The frequent alteration of human leucocyte antigen (HLA) class I molecule expression observed in non-Hodgkin's lymphomas (NHL), similarly to solid tumours, has been reported to favour tumoral escape from the immune system. In order to identify the underlying mechanisms, we analysed 15 HLA defective NHL including partial (n = 10) and total class I (n = 5) loss, as well as HLA class II defects (n = 5). The HLA defect concerned HLA-A and -B antigens in 14 of 15 cases. In the cases with partial defect, the use of specific allelic monoclonal antibodies detected a defect of both alleles of A or B loci in six of seven tested cases. Allelic reverse transcription polymerase chain reaction (RT-PCR) demonstrated defects in six of nine cases, including four alterations of both A and B mRNA alleles. Real-time quantitative RT-PCR (RQ-PCR) did not detect the HLA-DR transcript in the two negative HLA-DR lymphomas, contrasting with the presence of CMH II transactivator (CIITA) transcript. Loss of heterozygosity (LOH) was detected in nine of 14 cases through variable pattern of nine microsatellites markers of the HLA locus. Taken together, these findings demonstrate the complexity and the variability of the mechanisms underlying HLA protein deficiencies with a high frequency of LOH. The diversity of these mechanisms indicates the importance of positive selection of HLA altered clones in the development of these NHL cases. Copyright 2004 Blackwell Publishing Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384976     DOI: 10.1111/j.1365-2141.2004.05151.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.

Authors:  Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

2.  Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid.

Authors:  Faisal F Y Radwan; Azim Hossain; Jason M God; Nathan Leaphart; Michelle Elvington; Mitzi Nagarkatti; Stephen Tomlinson; Azizul Haque
Journal:  J Cell Biochem       Date:  2015-01       Impact factor: 4.429

Review 3.  Genetic lesions in diffuse large B-cell lymphomas.

Authors:  M Testoni; E Zucca; K H Young; F Bertoni
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

Review 4.  Ly49 receptors: innate and adaptive immune paradigms.

Authors:  Mir Munir A Rahim; Megan M Tu; Ahmad Bakur Mahmoud; Andrew Wight; Elias Abou-Samra; Patricia D A Lima; Andrew P Makrigiannis
Journal:  Front Immunol       Date:  2014-04-02       Impact factor: 7.561

5.  HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis.

Authors:  María García-Álvarez; Miguel Alcoceba; Miriam López-Parra; Noemí Puig; Alicia Antón; Ana Balanzategui; Isabel Prieto-Conde; Cristina Jiménez; María E Sarasquete; M Carmen Chillón; María Laura Gutiérrez; Rocío Corral; José María Alonso; José Antonio Queizán; Julia Vidán; Emilia Pardal; María Jesús Peñarrubia; José M Bastida; Ramón García-Sanz; Luis Marín; Marcos González
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

Review 6.  Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.

Authors:  Benedetta Apollonio; Nikolaos Ioannou; Despoina Papazoglou; Alan G Ramsay
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

Review 7.  Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond.

Authors:  Simona Pagliuca; Carmelo Gurnari; Marie Thérèse Rubio; Valeria Visconte; Tobias L Lenz
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

Review 8.  Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Authors:  Marie de Charette; Roch Houot
Journal:  Haematologica       Date:  2018-07-13       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.